Elanco Animal Health Incorporated (NYSE:ELAN) Stock Has Consensus Price Target of $29.42

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $29.42.

A number of research analysts recently weighed in on ELAN shares. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. The Goldman Sachs Group began coverage on Elanco Animal Health in a report on Friday, October 16th. They issued a “buy” rating and a $32.00 target price for the company. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. Finally, UBS Group upped their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $22.55 on Thursday. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $23.23 and its two-hundred day moving average is $23.56. Elanco Animal Health has a 12-month low of $19.40 and a 12-month high of $27.98. The stock has a market capitalization of $11.27 billion, a price-to-earnings ratio of -55.00, a PEG ratio of 2.00 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health will post 1.13 EPS for the current year.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the purchase, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy Bettington sold 4,350 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider directly owned 138,911 shares in the company, valued at approximately $3,194,953. This represents a 3.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have acquired 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Anchor Investment Management LLC purchased a new stake in shares of Elanco Animal Health during the 2nd quarter worth approximately $29,000. Integrated Wealth Concepts LLC purchased a new position in Elanco Animal Health in the 2nd quarter valued at approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Elanco Animal Health in the 2nd quarter valued at approximately $38,000. Root Financial Partners LLC purchased a new position in Elanco Animal Health in the 3rd quarter valued at approximately $41,000. Finally, Bessemer Group Inc. raised its holdings in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.